查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1504256

有效性實驗的全球市場:評估 - 各服務形式，各用途，各終端用戶，各地區，機會，預測，2017～2031年

Efficacy Testing Market Assessment, By Service Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 221 Pages | 商品交期: 3-5個工作天內

價格

全球功效測試市場規模預計將從 2023 年的 3.6663 億美元增至 2031 年的 6.4629 億美元，預計 2024-2031 年的複合年增長率為 7.34%。突破性新藥和治療方法的出現推動了功效測試市場的擴大。藥品和化妝品法規強調產品安全，並重點確保活性藥物成分 (API) 的有效性。該市場專注於藥品的監管合規性和驗證，結合了防腐功效測試 (PET) 等多種方法。這些方法是透過監管機構、標準機構、行業協會和各個公司之間的合作多年來不斷發展的。這些監管機構的主要目標是遵守高文件標準和科學法規。由於新興國家尚未開發的市場潛力和巨大的成長前景，人們正在對這些國家進行大量投資。

各製藥公司、研究機構和政府支持之間正在採取聯盟、聯合研究、合約和併購等策略。 2022 年 3 月，PFNonwritings 和 Smart Plastic Technologies 簽訂了獨家共同開發協議，將 Smart Plastic 正在申請專利的 SPTek ECLIPSE 技術納入 PFNonwritings 的衛生和醫用無紡布產品中。經過徹底的產品研究和功效測試，該協議標誌著在醫療和衛生應用非織造布中使用生物合成代謝材料邁出了一步。

在全球對創新藥物和治療方法不斷增長的需求的推動下，全球功效測試市場有望成長。這項需求源自於癌症、糖尿病、結核病和心臟病等慢性病和傳染病的日益普及。經常受到慢性病影響的老年人口不斷增加，也促使對新藥物和治療方法的需求增加。政府措施將改善醫療保健基礎設施並促進製藥業和功效測試市場的成長。此外，遺傳疾病和癌症發生率的上升也推動了對個人化藥物的需求。此外，對傳染病易感性的個體差異以及預後和治療設計的個體間不可預測性促使對個人化藥物的需求不斷增長。由於患者數量眾多，個別行為和身體反應存在很大差異，凸顯了對個人化藥物以提高療效的需求，從而推動了藥物療效測試的需求。

本報告提供全球有效性測試市場的相關調查，提供市場概要，以及各服務形式，各用途，各終端用戶，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 調查手法

第2章 計劃的範圍和定義

第3章 摘要整理

第4章 全球有效性測試市場的展望，2017～2031年

  • 市場規模·預測
  • 各服務形式
  • 各用途
  • 各終端用戶
  • 各地區
  • 各企業市場佔有率(%)、2023年

第5章 全球有效性測試市場的展望，各地區，2017～2031年

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第6章 市場製圖，2023年

第7章 宏觀環境·產業結構

  • 需求供給分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL分析
  • 波特的五力分析

第8章 市場動態

第9章 法規結構和革新

第10章 主要加入企業的形勢

第11章 價格分析

第12章 案例研究

第13章 主要加入企業的展望

  • Eurofins Viracor
  • River Laboratories International, Inc.
  • Becton, Dickinson and Company
  • Societe Generale de Surveillance
  • Merck KGaA
  • bioMerieux SA
  • Pacific Biolabs Inc
  • WuXi AppTec
  • North American Science Associates LLC
  • Accugen Laboratories, Inc.

第14章 策略性建議

第15章 公司概要·免責聲明

Product Code: MX11532

Global efficacy testing market is projected to witness a CAGR of 7.34% during the forecast period 2024-2031, growing from USD 366.63 million in 2023 to USD 646.29 million in 2031. The expansion of the efficacy testing market is propelled by the advent of revolutionary, novel drugs and therapies. Regulations governing pharmaceutical and cosmetic products emphasize product safety, with a central focus on ensuring the efficacy of the active pharmaceutical ingredient (API). The marketplaces significance on regulatory compliance and validation of pharmaceutical products, incorporating diverse approaches such as preservative efficacy testing (PET). These methods have evolved over the years through collaboration among regulatory agencies, standards organizations, industry groups, and individual companies. The primary objective of these regulatory entities is to adhere to high documentation standards and scientific regulations. Significant investments are being made in emerging economies, driven by the untapped potential and substantial growth prospects in markets that are yet to be fully explored.

Strategies, such as partnerships, collaborations, agreements, and mergers and acquisitions, are taking place between different pharmaceutical companies, research institutes, and government support. In March 2022, PFNonwovens and Smart Plastic Technologies entered an exclusive joint development agreement to incorporate Smart Plastic's patent pending SPTek ECLIPSE technology into PFNonwovens' hygiene and medical nonwoven products. This agreement marked a step toward utilizing bio-assimilated materials in nonwovens for medical and hygiene applications, following thorough research and efficacy testing of the products.

In August 2022, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. engaged in a global licensing arrangement with Merck to utilize Biocytogen's RenMice(TM) platform. As per the agreement, Merck gained complete access to Biocytogen's RenMice(TM) platform for the exploration and advancement of fully human antibody therapeutics across an extensive array of drug targets.

Rising Demand for Novel Drugs and Therapies

The global efficacy testing market is poised for growth, driven by the increasing demand for innovative drugs and therapies worldwide. This demand emerges from the increasing prevalence of chronic and infectious diseases like cancer, diabetes, tuberculosis, and heart diseases. The expanding geriatric population, often afflicted with chronic conditions, contributes to the increased demand for novel drugs and therapies. Government initiatives will improve healthcare infrastructure and fuel the growth of the pharmaceutical industry and efficacy testing market. Moreover, the rising incidence of genetic disorders and cancer is driving the demand for personalized drugs as well. Additionally, the varying susceptibility of individuals to infections and the inter-individual unpredictability in designing prognosis and treatments contribute to the growing need for personalized medicines. The substantial patient pool results in significant variations in individual behavior and bodily response, highlighting the demand for personalized medicines to enhance efficacy and, consequently, driving the demand for drug efficacy testing.

For instance, on July 26, 2023, the EU Commission published Regulation (EU) 2023/1545 amending Cosmetic Regulation (EC) 1223/2009 concerning allergens. This update includes new substances and revised restrictions on Cosmetic Product Labelling, expanding the number of allergens to be indicated in the INCI list of a finished cosmetic product if present at levels greater than 0.001% for leave-on products or 0.01% for rinse-off products.

Growing Adoption of Quality by Design (QbD) Approach

The healthcare sector is currently witnessing a notable trend as pharmaceutical and biotechnological companies increasingly embrace the quality by design (QbD) approach. This adoption stems from the critical emphasis on ensuring the stability and efficacy of drugs, both for patients and the companies. Many organizations are integrating the QbD approach to systematically identify, explain, and manage all sources of variability affecting a process, thereby safeguarding the quality of drugs. This ensures that the finished medicine consistently adheres to predefined performance characteristics right from the outset. Since the inception of QbD concepts, the industry has promptly embraced them to guarantee the quality of pharmaceutical and biotechnological products in compliance with regulatory requirements, employing approved research and development (R&D) and manufacturing procedures. Numerous quality requirements have been made mandatory for pharmaceutical or biotechnological products. The QbD approach has proven to be advantageous for pharmaceutical and biopharmaceutical companies, emphasizing that enhancing drug quality requires more than just increasing tests, thereby a proper R&D approach is indispensable.

A study in July 2023 highlighted that incorporating the Quality by Design (QbD) principle in the development of bilayer tablets will enhance product design and improve the quality, safety, and efficacy of drug products. According to the study, bilayer tablets have shown promising results for the development of fixed-dose combination (FDC) formulations.

Dominance of Pharmaceutical Manufacturing Applicants

The segment focusing on pharmaceutical manufacturing by application is poised for substantial growth in the forecast period. Clinical testing of drugs not only validates their performance and safety, but also enhances the credibility and authority of their packaging and marketing. The rising usage of drugs and vaccines contributes to an increased demand for efficacy testing, consequently propelling the growth of this segment. A considerable amount of testing and trials is required to give support to a newly developed drug throughout its manufacturing process. From discovery to development, and till the launch of a drug, a manufacturing company makes sure to pass its drug through many different phases and trials. Consequently, numerous companies are placing emphasis on efficacy testing for drugs in every phase. Efficacy testing, integral to drug research and development, verifies claims made on packaging or in marketing and ensures the intended use of the product. Preservative efficacy tests, crucial for confirming the safety of topical drugs for direct skin application, are also conducted. The mandatory regulation of these tests creates numerous opportunities for drug related efficacy testing.

Various countries are implementing rules and regulations to ensure compliance with claims made about drugs and vaccines. For example, Pfizer-BioNTech COVID-19 vaccine in May 2022, exhibited robust immune response, notable efficacy, and favorable safety in children aged 6 months to under 5 years after the administration of the third dose. The descriptive analysis revealed a vaccine efficacy of 80.3% during the period when the Omicron variant was predominant.

North America is Dominating the Global Efficacy Testing Market

Throughout the forecast period, North America is expected to lead the efficacy testing market, driven by factors such as increased research and development (R&D) activities and the widespread adoption of the quality by design (QbD) approach among regional market players. The pharmaceutical sector in North America is increasingly emphasizing outsourcing to contract research organizations (CROs) for drug development. Additionally, investments by government in contract development and manufacturing organizations (CDMO), drug substance, and drug product manufacturing capacities contribute to this dominance. The region boasts a well-established pharmaceutical industry, substantial R&D spending, a strong presence of major service providers, and a growing inclination among pharmaceutical and cosmetic companies to outsource analytical testing. According to OECD, in October 2022, pharmaceutical spending as a percentage of gross domestic product (GDP) was 2.08%, 1.72%, and 1.34% in the United States, Canada, and Mexico, respectively. This highlights the significant involvement of major players, manufacturers, and government organizations in product development, fostering demand for efficacy testing services and contributing to the overall growth of the examined market.

Future Market Scenario (2024 - 2031F)

Growth in demand of novel drugs and therapies to tackle numerous diseases presents the biggest opportunity for the efficacy testing market. Adoption of advanced and effective approaches have been devised to ensure the efficacy of APIs, which presents yet another opportunity in the market. R&D and heavy investments made by governments and healthcare companies is promoting developments in the efficacy testing market, and new labs and brands in this area of development are introducing advanced technologies, which, in turn, is propelling the market. For instance, SkinScience Analytics aims to transform the testing domain through its dedication to stringent scientific methodologies and commitment towards consumer welfare. Launched in August 2023 and based in Tucson, AZ, the lab specializes in various essential tests for product safety, encompassing the human repeat insult patch test (HRIPT), cumulative irritation testing, and safety-in-use evaluations.

Key Players Landscape and Outlook

Numerous companies, such as Eurofins Viracor, River Laboratories International, Inc., Becton, Dickinson and Company, Societe Generale de Surveillance, Merck KGaA, bioMerieux SA, Pacific Biolabs Inc, WuXi AppTec, North American Science Associates LLC, Accugen Laboratories, Inc., etc., are directing their attention towards organic growth initiatives, including product launches, approvals, and endeavors like patents and events. Organic growth strategies observed in the market include acquisitions, partnerships, and collaborations. These initiatives have facilitated the expansion of business operations and the customer base for efficacy testing market players. Market players in the efficacy testing market are poised to encounter promising growth prospects in the global market. The primary focus of these leading players is directed towards the rapidly expanding market segment, aiming to thrive and excel in a competitive market environment. Additionally, these market players emphasize collaboration and license agreements as strategic initiatives that are anticipated to propel market growth.

In June 2022, SGS inaugurated a dedicated biosafety level-2 microbiological laboratory within its testing facility in Phoenix, Arizona. Occupying approximately 4,000 square feet within the 12,000-square-foot building, this new laboratory will specialize in conducting efficacy testing for hand sanitizer and antibacterial hand soap.

In June 2022, Eurofins Cosmetics & Personal Care acquired CRA Korea Inc., a clinical testing laboratory situated in South Korea. This laboratory predominantly specializes in delivering safety and efficacy studies, consumer tests and personal care industry.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Efficacy Testing Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Service Type
    • 4.2.1. Antimicrobial/ Preservative Efficacy Testing
      • 4.2.1.1. Traditional Test Methods
      • 4.2.1.2. Rapid Test Methods
    • 4.2.2. Disinfectant Efficacy Testing
      • 4.2.2.1. Surface Test Methods
      • 4.2.2.2. Suspension Test Methods
  • 4.3. By Application
    • 4.3.1. Pharmaceutical Manufacturing
    • 4.3.2. Cosmetics and Personal Care Products
    • 4.3.3. Consumer Products
    • 4.3.4. Medical Devices
  • 4.4. By End-user
    • 4.4.1. Pharmaceutical Companies
    • 4.4.2. Laboratories
    • 4.4.3. Research Institutes
    • 4.4.4. Others
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia-Pacific
    • 4.5.4. South End-user America
    • 4.5.5. Middle East and Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Efficacy Testing Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Service Type
      • 5.1.2.1. Antimicrobial/ Preservative Efficacy Testing
        • 5.1.2.1.1. Traditional Test Methods
        • 5.1.2.1.2. Rapid Test Methods
      • 5.1.2.2. Disinfectant Efficacy Testing
        • 5.1.2.2.1. Surface Test Methods
        • 5.1.2.2.2. Suspension Test Methods
    • 5.1.3. By Application
      • 5.1.3.1. Pharmaceutical Manufacturing
      • 5.1.3.2. Cosmetics and Personal Care Products
      • 5.1.3.3. Consumer Products
      • 5.1.3.4. Medical Devices
    • 5.1.4. By End-user
      • 5.1.4.1. Pharmaceutical Companies
      • 5.1.4.2. Laboratories
      • 5.1.4.3. Research Institutes
      • 5.1.4.4. Others
    • 5.1.5. United States*
      • 5.1.5.1. Market Size & Forecast
        • 5.1.5.1.1. By Value
        • 5.1.5.1.2. By Volume
      • 5.1.5.2. By Service Type
        • 5.1.5.2.1. Antimicrobial/ Preservative Efficacy Testing
          • 5.1.5.2.1.1. Traditional Test Methods
          • 5.1.5.2.1.2. Rapid Test Methods
        • 5.1.5.2.2. Disinfectant Efficacy Testing
          • 5.1.5.2.2.1. Surface Test Methods
          • 5.1.5.2.2.2. Suspension Test Methods
      • 5.1.5.3. By Application
        • 5.1.5.3.1. Pharmaceutical Manufacturing
        • 5.1.5.3.2. Cosmetics and Personal Care Products
        • 5.1.5.3.3. Consumer Products
        • 5.1.5.3.4. Medical Devices
      • 5.1.5.4. By End-user
        • 5.1.5.4.1. Pharmaceutical Companies
        • 5.1.5.4.2. Laboratories
        • 5.1.5.4.3. Research Institutes
        • 5.1.5.4.4. Others
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Service Type
  • 6.2. By Application
  • 6.3. By End-user
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Patent Landscape
  • 9.2. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Eurofins Viracor
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. River Laboratories International, Inc.
  • 13.3. Becton, Dickinson and Company
  • 13.4. Societe Generale de Surveillance
  • 13.5. Merck KGaA
  • 13.6. bioMerieux SA
  • 13.7. Pacific Biolabs Inc
  • 13.8. WuXi AppTec
  • 13.9. North American Science Associates LLC
  • 13.10. Accugen Laboratories, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 2. Global Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 4. Global Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 5. Global Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 6. Global Efficacy Testing Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 8. North America Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 10. North America Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 11. North America Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 12. North America Efficacy Testing Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 14. United States Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 16. United States Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 17. United States Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 18. Canada Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 19. Canada Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 21. Canada Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 22. Canada Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 23. Mexico Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 24. Mexico Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 26. Mexico Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 27. Mexico Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 28. Europe Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 29. Europe Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 31. Europe Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 32. Europe Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Efficacy Testing Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 35. Germany Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 37. Germany Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 38. Germany Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 39. France Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 40. France Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 42. France Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 43. France Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 44. Italy Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 45. Italy Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 47. Italy Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 48. Italy Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 49. United Kingdom Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 50. United Kingdom Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 52. United Kingdom Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 53. United Kingdom Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 54. Russia Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 55. Russia Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 57. Russia Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 58. Russia Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 59. Netherlands Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 60. Netherlands Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 62. Netherlands Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 63. Netherlands Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 64. Spain Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 65. Spain Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 67. Spain Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 68. Spain Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 69. Turkey Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 70. Turkey Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 72. Turkey Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 73. Turkey Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 74. Poland Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 75. Poland Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 77. Poland Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 78. Poland Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 79. South America Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 80. South America Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 82. South America Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 83. South America Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 84. South America Efficacy Testing Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 86. Brazil Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 88. Brazil Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 89. Brazil Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 90. Argentina Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 91. Argentina Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 93. Argentina Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 94. Argentina Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 95. Asia-Pacific Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 96. Asia-Pacific Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 98. Asia-Pacific Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 99. Asia-Pacific Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 100. Asia-Pacific Efficacy Testing Market Share (%), By Country, 2017-2031F
  • Figure 101. India Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 102. India Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 104. India Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 105. India Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 106. China Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 107. China Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 109. China Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 110. China Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 111. Japan Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 112. Japan Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 114. Japan Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 115. Japan Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 116. Australia Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 117. Australia Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 119. Australia Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 120. Australia Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 121. Vietnam Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 122. Vietnam Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 124. Vietnam Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 125. Vietnam Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 126. South Korea Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 127. South Korea Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 129. South Korea Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 130. South Korea Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 131. Indonesia Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 132. Indonesia Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 134. Indonesia Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 135. Indonesia Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 136. Philippines Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 137. Philippines Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 139. Philippines Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 140. Philippines Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 141. Middle East & Africa Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 142. Middle East & Africa Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 144. Middle East & Africa Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 145. Middle East & Africa Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 146. Middle East & Africa Efficacy Testing Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 148. Saudi Arabia Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 150. Saudi Arabia Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 151. Saudi Arabia Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 152. UAE Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 153. UAE Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 155. UAE Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 156. UAE Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 157. South Africa Efficacy Testing Market, By Value, in USD Million, 2017-2031F
  • Figure 158. South Africa Efficacy Testing Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Efficacy Testing Market Share (%), By Service Type, 2017-2031F
  • Figure 160. South Africa Efficacy Testing Market Share (%), By Application, 2017-2031F
  • Figure 161. South Africa Efficacy Testing Market Share (%), By End-user, 2017-2031F
  • Figure 162. By Service Type Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 163. By Application Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 164. By End-user Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Million) & Growth Rate (%), 2023